Pfizer Oncology, New London, CT, USA.
Clin Lung Cancer. 2009 Jul;10(4):273-80. doi: 10.3816/CLC.2009.n.038.
Figitumumab (CP-751,871) is a fully human immunoglobulin G2 monoclonal antibody highly potent and specific against the insulin-like growth factor-1 receptor. Figitumumab has an effective half-life of approximately 20 days, and it has been well tolerated in clinical studies when given alone or in combination with chemotherapy and targeted agents. Mild to moderate asymptomatic hyperglycemia is observed with figitumumab therapy, but it is generally manageable and well tolerated. Because of its extended half-life and absence of dose-limiting toxicity and hypersensitivity, figitumumab compares well to other compounds in its class. Furthermore, recent data suggest that figitumumab might be active in combination with platinum doublets for the treatment of chemotherapy-naive non-small-cell lung cancer (NSCLC). This article discusses the results to date of the figitumumab development program and the rationale for further testing of this agent as a therapeutic option for the treatment of patients with NSCLC.
法替莫单抗（CP-751,871）是一种针对胰岛素样生长因子-1 受体的高亲和力和特异性的完全人源化 IgG2 单克隆抗体。法替莫单抗的有效半衰期约为 20 天，在单独使用或与化疗药物和靶向药物联合使用时，在临床试验中具有良好的耐受性。法替莫单抗治疗时会出现轻度至中度无症状性高血糖，但通常易于管理且耐受性良好。由于其半衰期延长，且无剂量限制毒性和过敏反应，法替莫单抗与同类其他化合物相比具有优势。此外，最近的数据表明，法替莫单抗可能与铂类双重药物联合用于治疗未经化疗的非小细胞肺癌（NSCLC）。本文讨论了法替莫单抗开发项目的现有结果，以及进一步测试该药物作为治疗 NSCLC 患者的治疗选择的理论基础。
